Ban on Youth Gender-Affirming Care

Summary#

The Chloe Cole Act would bar health care professionals, hospitals, and clinics from taking part in what the bill calls “chemical or surgical mutilation” of anyone under 18. It also creates a federal civil lawsuit right for people who were treated as children and for their parents or guardians to recover damages. The bill defines banned actions, lists limited medical exceptions, and sets rules for proof and liability.

• Main change: It makes certain puberty blockers, cross-sex hormones, and surgical procedures for minors illegal in covered circumstances and lets harmed children and their parents sue in federal court.
• Who decides exceptions: A provider may only start a treatment that fits an exception after finding “clear and convincing evidence” that the exception applies.
• Federal reach: The ban applies when the care involves interstate commerce, travel, communications, items that crossed state lines, or occurs in federal jurisdictions (for example, Washington, D.C., or U.S. territories).
• Liability: Providers can face strict liability if a prohibited act is shown by clear and convincing evidence. Damages may include medical costs, emotional harm, and punitive damages.
• Long deadline to sue: A person can file suit up to 25 years after their 18th birthday or within 4 years after paying for detransition treatment, whichever is later.

What it means for you#

• Children who receive puberty-related care

  • Such care from doctors or clinics could become illegal under federal law if it fits the bill’s definition and one of the commerce conditions applies.
  • If a child was treated before the law, the child (or parents) can still sue later under the bill.

• Parents and legal guardians

  • Parents may bring federal lawsuits on behalf of children who were treated as minors.
  • Parents who later pay for detransition care may have an extended period to bring a claim.

• Health care professionals (including mental health professionals)

  • Doctors who prescribe puberty blockers or hormones, perform certain surgeries, authorize those procedures, or supervise them in covered circumstances could face civil liability.
  • Providers must be able to show by clear and convincing evidence that any exception (for example, a disorder of sexual development) applies before beginning treatment that might otherwise be banned.
  • Counseling, opinions, and referrals are explicitly not a basis for suit so long as they do not cross into the bill’s defined forms of participation.

• Hospitals and clinics

  • Hospitals and clinics that provide, authorize, or coordinate the specified treatments in covered circumstances could be sued and held strictly liable if the conduct is proven by clear and convincing evidence.

• Insurers and payers

  • The bill could lead to claims for the cost of medical care to correct or reverse past treatments. This could affect insurers’ exposure, although the bill does not directly change insurance rules.

• Telemedicine and interstate care

  • Because the ban applies when treatments or communications cross state lines, telehealth prescriptions, mail-order medications, or travel for care may fall under the law’s reach. This could limit access across state lines.

Expenses#

No publicly available information.

• The bill creates a new private right of action that could increase federal civil litigation related to these medical treatments.
• Potential private costs could include damages awards, legal defense costs for providers and institutions, and higher liability insurance premiums for providers who treat related conditions.
• Possible administrative costs for providers include additional documentation and legal review to meet the “clear and convincing” evidence requirement for exceptions.
• The bill does not include a federal enforcement agency budget or direct government spending in the text.

Proponents' View#

The bill text and title indicate the policy goals and how supporters might present them:

• The bill appears intended to prohibit minors from receiving irreversible or body-altering medical treatments aimed at changing sex characteristics.
• A possible argument for the bill is that it would protect children from medical interventions the drafters view as harmful or experimental for minors.
• The private right of action and strict liability provisions could be seen as providing a remedy and deterrent if providers perform treatments the bill bans.
• The clear definitions and listed exceptions are designed to limit the ban to treatments specifically aimed at altering sex characteristics, while allowing certain medical care for disorders of sexual development and for detransition care.

Opponents' View#

Based only on the bill text and its design, here are possible concerns and trade-offs the bill raises:

• One concern is that the bill’s definitions and the broad interstate-commerce triggers could cover common medical practices like telemedicine, prescriptions that cross state lines, or out-of-state travel for care. This could greatly expand federal reach into medical licensing and care decisions that states typically handle.
• The bill requires providers to prove exceptions by “clear and convincing evidence” before starting care. This higher proof standard could delay or deter medically recommended treatment that providers consider necessary.
• The private right of action with strict liability and long time limits (up to 25 years after age 18) may expose many providers and institutions to large damages and long-running litigation risk.
• Although counseling and referrals are explicitly not a basis for suit, the bill resolves ambiguities against defendants. This could chill doctors’ and mental health professionals’ willingness to discuss or recommend care, for fear of legal risk.
• It is unclear how courts should apply the bill’s medical definitions (for example, its definition of “sex” tied to conception) in complex medical cases, or how existing medical standards of care should factor into liability when past standards differed.
• The bill does not include procedures for federal oversight or funding to help providers comply, nor does it provide a fiscal estimate of the likely legal or health system impacts.